Clinical Trial Update: Clinical Utility of FES F18 PET/CT in Metastatic Breast Cancer Patients

View source ↗

Summary

A GE Healthcare-sponsored trial evaluating the clinical utility of 18F-fluoroestradiol (FES) PET/CT in metastatic breast cancer has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• FES F18 PET/CT (18F-fluoroestradiol (FES) PET/CT)

Snippet

Sponsor: GE Healthcare | Conditions: Metastatic Breast Cancer | Status: TERMINATED